Literature DB >> 19115420

A novel Global Assessment Scale for Wilson's Disease (GAS for WD).

Annu Aggarwal1, Nitin Aggarwal, Aabha Nagral, Govindji Jankharia, Mohit Bhatt.   

Abstract

Wilson's disease (WD) is an inherited disorder of copper metabolism. Despite being treatable, patients with WD suffer severe disabilities due to delay in initiation and difficulty in monitoring treatment. We propose a two tier, Global Assessment Scale for Wilson's Disease (GAS for WD) that grades the multisystemic manifestations of the disease. Tier 1 scores the global disability in four domains: Liver, Cognition and behavior, Motor, and Osseomuscular. Tier 2 is multidimensional scale for a fine grained evaluation of the neurological dysfunction. We prospectively validated this scale in 30 patients with WD. Both tiers had a high inter-rater reliability (Intraclass correlation coefficient ICC (A, 2) = 0.96-1.0). Tier 2 items were internally consistent (Cronbach's alpha = 0.89) and factorial analysis showed that 90.3% of the Tier 2 total score variance was determined by seven factors. Scores of both tiers were commensurate with the disease burden as assessed by standard disability scales (Child Pugh, UPDRS, SS3, and CGI) and satisfied criteria for validity. Longitudinal follow-up over 1.5 years showed that the scale was sensitive to clinical change. This suggests that GAS for WD is a practical tool with potential applications in management of patients, and in testing and comparison of treatment regimens. 2008 Movement Disorder Society

Entities:  

Mesh:

Year:  2009        PMID: 19115420     DOI: 10.1002/mds.22231

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

Review 2.  Clinical presentations of Wilson disease.

Authors:  Samuel Shribman; Thomas T Warner; James S Dooley
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

4.  Disappearance of Clinical and Imaging Manifestations in Wilson's Disease with Ammonium Tetrathiomolybdate and Zinc.

Authors:  Ignacio J Posada; Ana Ramos
Journal:  Mov Disord Clin Pract       Date:  2021-11-10

5.  Analysis of Wilson disease mutations in copper binding domain of ATP7B gene.

Authors:  Bushra Gul; Sabika Firasat; Raeesa Tehreem; Tayyaba Shan; Kiran Afshan
Journal:  PLoS One       Date:  2022-06-28       Impact factor: 3.752

6.  Osteoporosis and bone mineral density in patients with Wilson's disease: a systematic review and meta-analysis.

Authors:  J Chenbhanich; C Thongprayoon; A Atsawarungruangkit; T Phupitakphol; W Cheungpasitporn
Journal:  Osteoporos Int       Date:  2017-11-06       Impact factor: 4.507

7.  Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson's disease with D-penicillamine treatment failure.

Authors:  Dingbang Chen; Xiangxue Zhou; Haiman Hou; Li Feng; JunXiu Liu; Yinyin Liang; Xiaopu Lin; Jiwei Zhang; Chao Wu; Xiuling Liang; Zhong Pei; Xunhua Li
Journal:  Ther Adv Neurol Disord       Date:  2016-04-07       Impact factor: 6.570

Review 8.  Genetics of Wilson's disease: a clinical perspective.

Authors:  S Suresh Kumar; George Kurian; C E Eapen; Eve A Roberts
Journal:  Indian J Gastroenterol       Date:  2012-09-01

Review 9.  The Pragmatic Treatment of Wilson's Disease.

Authors:  Annu Aggarwal; Mohit Bhatt
Journal:  Mov Disord Clin Pract       Date:  2014-04-10

10.  Designing Clinical Trials in Wilson's Disease.

Authors:  Peter Ott; Aurélia Poujois; Thomas Damgaard Sandahl; Karl Heinz Weiss; Peter Ferenci; Michael L Schilsky; Aftab Ala; Frederick K Askari; Anna Czlonkowska; Ralf-Dieter Hilgers; Eve A Roberts
Journal:  Hepatology       Date:  2021-10-05       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.